Dova Pharmaceuticals to Present at the UBS Global Healthcare Conference
DURHAM, N.C., May 20, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the UBS Global Healthcare Conference on Monday, May 20, 2019 at 2:00 p.m. ET in New York, NY.
A live audio webcast of the event will be available via the "Investor Relations" page of the Dova website, . Please log on through Dova's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Dova's website for 90 days following the call.
About Dova Pharmaceuticals, Inc.
Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dova’s proprietary pipeline includes one commercial product, DOPTELET®, for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.
Contacts
Mark W. Hahn
(919) 338-7936
Westwicke
John Woolford
(443) 213-0506
